These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 9153534)
1. CAG repeat number governs the development rate of pathology in Huntington's disease. Penney JB; Vonsattel JP; MacDonald ME; Gusella JF; Myers RH Ann Neurol; 1997 May; 41(5):689-92. PubMed ID: 9153534 [TBL] [Abstract][Full Text] [Related]
2. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea]. Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360 [TBL] [Abstract][Full Text] [Related]
3. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA Ann Neurol; 2001 Sep; 50(3):373-80. PubMed ID: 11558794 [TBL] [Abstract][Full Text] [Related]
4. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Furtado S; Suchowersky O; Rewcastle B; Graham L; Klimek ML; Garber A Ann Neurol; 1996 Jan; 39(1):132-6. PubMed ID: 8572659 [TBL] [Abstract][Full Text] [Related]
5. Regional specificity of brain atrophy in Huntington's disease. Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201 [TBL] [Abstract][Full Text] [Related]
6. Trinucleotide repeat length and rate of progression of Huntington's disease. Illarioshkin SN; Igarashi S; Onodera O; Markova ED; Nikolskaya NN; Tanaka H; Chabrashwili TZ; Insarova NG; Endo K; Ivanova-Smolenskaya IA Ann Neurol; 1994 Oct; 36(4):630-5. PubMed ID: 7944295 [TBL] [Abstract][Full Text] [Related]
7. Does CAG repeat number predict the rate of pathological changes in Huntington's disease? Rosenblatt A; Margolis RL; Becher MW; Aylward E; Franz ML; Sherr M; Abbott MH; Lian KY; Ross CA Ann Neurol; 1998 Oct; 44(4):708-9. PubMed ID: 9778276 [No Abstract] [Full Text] [Related]
8. Molecular analysis of the Huntington's disease gene in New Zealand. Whitefield JE; Williams L; Snow K; Dixon J; Winship I; Stapleton PM; Faull RM; Love DR N Z Med J; 1996 Feb; 109(1015):27-30. PubMed ID: 8606810 [TBL] [Abstract][Full Text] [Related]
9. [Huntington's disease: trinucleotide disease or polyglutamine disease?]. Ide K; Nukina N; Kanazawa I Rinsho Shinkeigaku; 1995 Dec; 35(12):1540-1. PubMed ID: 8752457 [TBL] [Abstract][Full Text] [Related]
11. Variation of selective gray and white matter atrophy in Huntington's disease. Jech R; Klempír J; Vymazal J; Zidovská J; Klempírová O; Růzicka E; Roth J Mov Disord; 2007 Sep; 22(12):1783-9. PubMed ID: 17579363 [TBL] [Abstract][Full Text] [Related]
12. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Stevanin G; Fujigasaki H; Lebre AS; Camuzat A; Jeannequin C; Dode C; Takahashi J; San C; Bellance R; Brice A; Durr A Brain; 2003 Jul; 126(Pt 7):1599-603. PubMed ID: 12805114 [TBL] [Abstract][Full Text] [Related]
13. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Butterworth NJ; Williams L; Bullock JY; Love DR; Faull RL; Dragunow M Neuroscience; 1998 Nov; 87(1):49-53. PubMed ID: 9722140 [TBL] [Abstract][Full Text] [Related]
14. The association of CAG repeat length with clinical progression in Huntington disease. Rosenblatt A; Liang KY; Zhou H; Abbott MH; Gourley LM; Margolis RL; Brandt J; Ross CA Neurology; 2006 Apr; 66(7):1016-20. PubMed ID: 16606912 [TBL] [Abstract][Full Text] [Related]
15. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Andrew SE; Goldberg YP; Kremer B; Telenius H; Theilmann J; Adam S; Starr E; Squitieri F; Lin B; Kalchman MA Nat Genet; 1993 Aug; 4(4):398-403. PubMed ID: 8401589 [TBL] [Abstract][Full Text] [Related]
16. Parameter-based assessment of spatial and non-spatial attentional deficits in Huntington's disease. Finke K; Bublak P; Dose M; Müller HJ; Schneider WX Brain; 2006 May; 129(Pt 5):1137-51. PubMed ID: 16504973 [TBL] [Abstract][Full Text] [Related]
17. [Expansion of triplet repeat and neurodegenerative disorders]. Kanazawa I Rinsho Shinkeigaku; 1994 Dec; 34(12):1224-6. PubMed ID: 7774118 [TBL] [Abstract][Full Text] [Related]
18. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Ruocco HH; Lopes-Cendes I; Li LM; Santos-Silva M; Cendes F Braz J Med Biol Res; 2006 Aug; 39(8):1129-36. PubMed ID: 16906288 [TBL] [Abstract][Full Text] [Related]
19. The relationship between CAG repeat length and clinical progression in Huntington's disease. Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767 [TBL] [Abstract][Full Text] [Related]
20. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Langbehn DR; Brinkman RR; Falush D; Paulsen JS; Hayden MR; Clin Genet; 2004 Apr; 65(4):267-77. PubMed ID: 15025718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]